Aquestive Therapeutics, Inc. financial data

Symbol
AQST on Nasdaq
Industry
Pharmaceutical Preparations
Location
30 Technology Drive, Warren, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
MonoSol Rx, Inc. (to 3/27/2008)
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 543 % +367%
Quick Ratio 43.6 % +141%
Debt-to-equity -285 % -85.6%
Return On Equity 62.9 % +468%
Return On Assets -34 % -64.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 91.2M shares +36.6%
Common Stock, Shares, Outstanding 91.2M shares +36.6%
Entity Public Float 82.7M USD +200%
Common Stock, Value, Issued 91K USD +35.8%
Weighted Average Number of Shares Outstanding, Basic 91.1M shares +40.8%
Weighted Average Number of Shares Outstanding, Diluted 91.1M shares +40.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 58.9M USD +22.6%
Research and Development Expense 18.3M USD +25.9%
Costs and Expenses 80M USD +14.4%
Operating Income (Loss) -21.1M USD +3.66%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -35.1M USD -193%
Income Tax Expense (Benefit) 101K USD -29.9%
Net Income (Loss) Attributable to Parent -35.2M USD -191%
Earnings Per Share, Basic -0.48 USD/shares -153%
Earnings Per Share, Diluted -0.44 USD/shares -91.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.9M USD +213%
Inventory, Net 7.02M USD -0.82%
Assets, Current 96.6M USD +127%
Property, Plant and Equipment, Net 3.85M USD -15.4%
Operating Lease, Right-of-Use Asset 5.31M USD -6.33%
Other Assets, Noncurrent 4.23M USD -22.4%
Assets 110M USD +85%
Accounts Payable, Current 7.57M USD -24.2%
Employee-related Liabilities, Current 3.46M USD +22.1%
Accrued Liabilities, Current 5.03M USD -8.1%
Contract with Customer, Liability, Current 1.05M USD -60.3%
Liabilities, Current 15.2M USD -37%
Long-term Debt and Lease Obligation 27.5M USD -17.8%
Contract with Customer, Liability, Noncurrent 20.3M USD -38.1%
Operating Lease, Liability, Noncurrent 5.11M USD -7.26%
Other Liabilities, Noncurrent 2.03M USD +1.09%
Liabilities 155M USD -4.31%
Retained Earnings (Accumulated Deficit) -346M USD -11.3%
Stockholders' Equity Attributable to Parent -45.4M USD +55.9%
Liabilities and Equity 110M USD +85%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD -218%
Net Cash Provided by (Used in) Financing Activities 81.7M USD
Net Cash Provided by (Used in) Investing Activities -29K USD -1350%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 91.2M shares +36.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 71.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.9M USD +213%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1M USD -31.6%
Deferred Tax Assets, Valuation Allowance 84.1M USD +0.32%
Deferred Tax Assets, Gross 84.7M USD +0.45%
Operating Lease, Liability 5.59M USD -4.85%
Depreciation 891K USD -18.9%
Payments to Acquire Property, Plant, and Equipment 29K USD +1350%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -35.2M USD -191%
Lessee, Operating Lease, Liability, to be Paid 9.36M USD -10.1%
Property, Plant and Equipment, Gross 47.2M USD -0.12%
Operating Lease, Liability, Current 482K USD +31.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.32M USD +4.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.28M USD +4.39%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.77M USD -17%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.35M USD +3.54%
Deferred Tax Assets, Operating Loss Carryforwards 27.1M USD -15.8%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33M USD +25.3%
Additional Paid in Capital 301M USD +44.6%
Amortization of Intangible Assets 118K USD -29.8%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 5.62M USD +127%
Interest Expense 9.09M USD +48.9%